Initial assessment of the COVID-19 vaccination's impact on case numbers, hospitalisations and deaths in people aged 80 years and older, 15 EU/EEA countries, December 2020 to May 2021

Prioritisation of elderly people in COVID-19 vaccination campaigns aimed at reducing severe outcomes in this group. Using EU/EEA surveillance and vaccination uptake, we estimated the risk ratio of case, hospitalisation and death notifications in people 80 years and older compared with 25-59-year-olds. Highest impact was observed for full vaccination uptake 80% or higher with reductions in notification rates of cases up to 65% (IRR: 0.35; 95% CI: 0.13-0.99), hospitalisations up to 78% (IRR: 0.22; 95% CI: 0.13-0.37) and deaths up to 84% (IRR: 0.16; 95% CI: 0.13-0.20).S

Effectiveness of the Czech Tax System

The first part of the paper discusses methodologies of measurement for the administrative and compliance costs of taxation. The next section analyzes the overall administrative costs of the Czech tax system. The results show that the overall administrative costs of the Czech tax system are approximately 1.5 % of the total tax revenue. The third part of the paper shows the measurement of the compliance cost in the Czech Republic. Our results show that the most effective Czech taxes for business taxpayers are the value added tax, the corporate income tax and the road tax. Relatively higher costs are connected with the personal income tax and real estate tax.tax policy, tax effectiveness, administrative costs, compliance costs, Czech Republic

Challenge Benchmarks For Verification Of Real-Time Programs

Real-time systems, and in particular safety-critical systems, are a rich source of challenges for the program verification community as software errors can have catastrophic consequences. Unfortunately, it is nearly impossible to find representative safety-critical programs in the public domain. This has been significant impediment to research in the field, as it is very difficult to validate new ideas or techniques experimentally. This paper presents open challenges for verification of real-time systems in the context of the Real-time Specification for Java. But, our main contribution is a family of programs, called CDx, which we present as an open source benchmark for the verification community. Copyright © 2010 ACM

Challenge benchmarks for verification of real-time programs

Real-time systems, and in particular safety-critical systems, are a rich source of challenges for the program verification community as software errors can have catastrophic consequences. Unfortunately, it is nearly impossible to find representative safety-critical programs in the public domain. This has been significant impediment to research in the field, as it is very difficult to validate new ideas or techniques experimentally. This paper presents open challenges for verification of real-time systems in the context of the Real-time Specification for Java. But, our main contribution is a family of programs, called CDx, which we present as an open source benchmark for the verification community

Clinical activity of patupilone in patients with pretreated advanced/metastatic colon cancer; results of a phase I dose escalation trial

Background: new agents that are active in patients with metastatic colorectal cancer are needed. Patupilone (EPO906; epothilone B) is a novel microtubule-stabilising agent. Methods: patients with advanced colon cancer who progressed after prior treatment regimens received intravenous patupilone (6.5-10.0 mg m(-2)) once every 3 weeks by a 20-min infusion (20MI), 24-h continuous infusion (CI-1D) or 5-day intermittent 16-h infusion (16HI-5D). Adverse events (AEs), dose-limiting toxicities (DLTs), pharmacokinetics and anti-tumour activity were assessed. Results: sixty patients were enrolled. The maximum tolerated dose (MTD) was not reached in the 20MI arm (n=31), as no DLTs were observed. Three patients in the CI-1D arm (n=26) experienced 1 DLT each at 7.5, 8.0 and 9.0 mg m(-2), but MTD was not reached. However, the prolonged 16HI-5D arm was terminated at 6.5 mg m(-2) after two of the three patients developed a DLT. Diarrhoea was the most common AE and DLT, with increased severity at the higher doses (9.0 and 10.0 mg m(-2)). Grade 3 or 4 diarrhoea was observed in 11 (35%) of the patients in the 20MI arm, 4 (15%) of the patients in the CI-1D arm and 2 (67%) of the patients in the 16HI-5D arm. Patupilone activity was observed in the 20MI arm with a disease control rate of 58%, including four confirmed partial responses. The disease control rate in CI-1D arm was 39%. Conclusion: patupilone given once every 3 weeks as a 20-min infusion had promising anti-tumour activity and manageable safety profile at doses that demonstrated therapeutic efficacy